A comprehensive view of Gilead Sciences Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Gilead completes acquisition of CymaBay Therapeutics for US$4.3B, enhancing its liver disease treatment portfolio with lead product candidate seladelpar for primary biliary cholangitis; CymaBay now a wholly owned subsidiary of Gilead
Published: March 22, 2024 by Business Wire
Gilead and Merus partner to discover novel antibody-based trispecific T-Cell engagers: Gilead will pay US$81.0M upfront for access to Merus' Triclonics platform for cancer treatment research, with potential payments of up to US$1.5B
Published: March 06, 2024 by Business Wire
Gilead to present new data on HIV, COVID-19 and viral hepatitis treatments at the 31st Conference on Retroviruses and Opportunistic Infections; the analyses from nearly 80 studies include research on Biktarvy, Veklury, and Hepcludex
Published: February 26, 2024 by Business Wire
Gilead Sciences to purchase CymaBay Therapeutics for US$4.3B to expand its liver disease portfolio; deal give Gilead access to Seladelpar, a promising drug for the treatment of primary biliary cholangitis slated for potential FDA approval in 2024
Published: February 12, 2024 by Business Wire
Morningstar names Gilead a top dividend stock, noting stellar profit margins with HIV/hepatitis C virus portfolio, which requires small salesforce and inexpensive manufacturing; however, smart future acquisitions among factors needed to return to growth
Published: January 22, 2024 by Victoria Advocate

Ask us about our Tissue & Hygiene market view

Trending Chart

Interactive chart with headline count